Beth C. Seidenberg
Director at Progyny; Director at Latigo Biotherapeutics; Director at Kyverna Therapeutics. Based in Thousand Oaks, California.
- Rank
- 6365th of 14,644
- Companies held
- 5
- Largest holding
- PGNY, 67.1% of total
- Latest SEC filing
- Aug 10, 2026
- Listed but not counted
- $394M
What the $15.2M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Progyny PGNY Common Stock | Indirectly (see filing footnote) | 227,906 | $35.45 | $8.1M | 53.0% | Form 4, May 23, 2024 |
| Vera Therapeutics VERA Class A Common Stock | Directly | 131,553 | $26.75 | $3.5M | 23.1% | Form 4, Oct 28, 2024 |
| Progyny PGNY Common Stock | Directly | 43,416 | $35.45 | $1.5M | 10.1% | Form 4, May 23, 2024 |
| Sagimet Biosciences SGMT Series A Common Stock | Directly | 84,768 | $9.62 | $815K | 5.3% | Form 4, Jul 18, 2023 |
| Progyny PGNY Common Stock | Indirectly (see filing footnote) | 17,162 | $35.45 | $608K | 4.0% | Form 4, Jun 9, 2023 |
| Sagimet Biosciences SGMT Series A Common Stock | Indirectly (see filing footnote) | 46,875 | $9.62 | $451K | 3.0% | Form 4, Jul 18, 2023 |
| Vera Therapeutics VERA Class A Common Stock | Through Samuel B. Seidenberg Irrevocable Trust | 4,012 | $26.75 | $107K | 0.7% | Form 4, Oct 28, 2024 |
| Kyverna Therapeutics KYTX Common Stock | Directly | 21,727 | $4.37 | $95K | 0.6% | Form 4, May 27, 2026 |
| Atara Biotherapeutics ATRA Common Stock | Directly | 4,628 split-adjusted | $6.34 | $29K | 0.2% | Form 4, May 31, 2023 |
| Atara Biotherapeutics ATRA Common Stock | Through Samuel B. Seidenberg Irrevocable Trust | 8 split-adjusted | $6.34 | $50 | 0.0% | Form 4, May 31, 2023 |
Share counts are the amounts Beth C. Seidenberg reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Beth C. Seidenberg's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Progyny PGNY Common Stock | Through KPCB XIII Associates, LLC Held by a company or fund the insider manages | 5,074,615 | $35.45 | $180M | — | Form 4, May 23, 2024 |
| Latigo Biotherapeutics LTGO Common Stock | Through Westlake BioPartners Fund I, L.P. Held by a company or fund the insider manages | 5,944,009 | $13.24 | $78.7M | — | Form 4, Aug 10, 2026 |
| Latigo Biotherapeutics LTGO Common Stock | Through Westlake BioPartners Fund II, L.P. Held by a company or fund the insider manages | 5,160,847 | $13.24 | $68.3M | — | Form 4, Aug 10, 2026 |
| Latigo Biotherapeutics LTGO Common Stock | Through Westlake BioPartners Opportunity Fund I, L.P. Held by a company or fund the insider manages | 2,094,813 | $13.24 | $27.7M | — | Form 4, Aug 10, 2026 |
| Sagimet Biosciences SGMT Series A Common Stock | Through KPCB PBD Associates, LLC Held by a company or fund the insider manages | 1,899,475 | $9.62 | $18.3M | — | Form 4, Jul 18, 2023 |
| Kyverna Therapeutics KYTX Common Stock | Through Westlake BioPartners Fund I, L.P. Held by a company or fund the insider manages | 3,787,940 | $4.37 | $16.6M | — | Form 4, May 27, 2026 |
| Kyverna Therapeutics KYTX Common Stock | Through Westlake BioPartners Opportunity Fund I, L.P. Held by a company or fund the insider manages | 869,317 | $4.37 | $3.8M | — | Form 4, May 27, 2026 |
| Atara Biotherapeutics ATRA Common Stock | Through KPCB XV Associates, LLC Held by a company or fund the insider manages | 72,889 split-adjusted | $6.34 | $462K | — | Form 4, May 31, 2023 |
| Atara Biotherapeutics ATRA Common Stock | Through KPCB XV Founders Fund, LLC Held by a company or fund the insider manages | 2,177 split-adjusted | $6.34 | $14K | — | Form 4, May 31, 2023 |
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 6362 | Dale W. Boyles CHIEF FINANCIAL OFFICER, Warrior Met Coal. Dallas, TX | $15.2M |
| 6363 | Kevin B. Habicht EVP, Chief Financial Officer, NNN REIT. Orange, FL | $15.2M |
| 6364 | Van A. Dukeman President and CEO, First Busey. Leawood, KS | $15.2M |
| 6365 | Beth C. Seidenberg Director, Progyny. Thousand Oaks, CA | $15.2M |
| 6366 | Murray R. Garnick EVP & General Counsel, Altria Group. Richmond, VA | $15.2M |
| 6367 | Michael Larry Snider President and COO, LGI Homes. The Woodlands, TX | $15.2M |
| 6368 | Fred E. Cohen Director, Kyverna Therapeutics. Brisbane, CA | $15.2M |
Other Progyny insiders
All PGNY insiders- Peter Anevski$25.2MCHIEF EXECUTIVE OFFICER. #4348 overall
- Norman Payson$16.5MDirector. #5971 overall
- Michael E. Sturmer$9.0MPRESIDENT. #9459 overall
- David J. Schlanger$8.5MExecutive Chairman. #9956 overall
- Fred E. Cohen$804KDirector. #6368 overall
Questions
How much stock does Beth C. Seidenberg own?
Beth C. Seidenberg holds $15,243,863 in listed stock based on SEC filings and current prices, mostly Progyny (PGNY). That ranks 6365th on the Stock Rich List.
Is this Beth C. Seidenberg's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Beth C. Seidenberg last buy or sell stock?
The most recent open-market trade on file is a purchase of 133,333 KYTX shares on Dec 18, 2025 at $7.50.